Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis-Reference-Cited by-同舟云学术

Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis

Published:2012-02-20 Issue:2 Volume:7 Page:e31784
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Harrer Andrea,Pilz Georg,Einhaeupl Max,Oppermann Katrin,Hitzl Wolfgang,Wipfler Peter,Sellner Johann,Golaszewski Stefan,Afazel Shahrzad,Haschke-Becher Elisabeth,Trinka Eugen,Kraus Joerg

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference38 articles.

1. The impact of interferon-beta treatment on the blood-brain barrier.;J Kraus;Drug Discov Today,2006

2. Alpha4 integrins as therapeutic targets in autoimmune disease.;UH von Andrian;N Engl J Med,2003

3. Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.;MJ Eikelenboom;J Neuroimmunol,2005

4. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.;P Wipfler;Mult Scler,2011

5. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.;TA Yednock;Nature,1992

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experimental laboratory biomarkers in multiple sclerosis;Wiener Medizinische Wochenschrift;2022-03-07

2. NKT and NKT-like Cells in Autoimmune Neuroinflammatory Diseases—Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome;International Journal of Molecular Sciences;2021-09-01

3. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring;Frontiers in Immunology;2020-09-24

4. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?;Neurotherapeutics;2019-08-26

5. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients;Neurology;2017-09-15